Bethesda IV thyroid nodule in a professional singer
A 38-year-old woman is referred with a 2.8 cm right thyroid nodule discovered incidentally. She has no compressive symptoms, no family history of thyroid cancer, and no neck irradiation. TSH is 1.8 mIU/L. Ultrasound shows a solid, hypoechoic nodule with irregular margins and microcalcifications; no suspicious lymph nodes. Fine-needle aspiration cytology is reported as Bethesda category IV (follicular neoplasm). She is anxious about cancer and asks for 'the whole thyroid to be removed' so she does not need a second surgery. She is a professional singer and worries about voice changes. Your institution has access to molecular testing (e.g., Afirma/Gene Expression Classifier) with a 2-week turnaround. She takes no medications, has normal calcium and parathyroid hormone levels, and is otherwise healthy.
1. What are the management options for Bethesda IV cytology in this patient, and how do you counsel her about total thyroidectomy versus diagnostic lobectomy?
Read the worked answer
Bethesda IV (follicular neoplasm) carries a 25–40% risk of malignancy, and the diagnosis cannot be made by cytology alone because capsular or vascular invasion is required. The standard approach is diagnostic lobectomy, not total thyroidectomy, because total thyroidectomy commits her to lifelong levothyroxine and carries a higher risk of recurrent laryngeal nerve injury and hypoparathyroidism, which is particularly relevant for a professional singer. Molecular testing (e.g., Afirma GEC or ThyroSeq) can refine the risk: a benign result has a high negative predictive value and may allow observation, while a suspicious result supports surgery. However, her ultrasound features (hypoechoic, irregular margins, microcalcifications) are suspicious, so even a benign molecular result may not completely rule out malignancy. I would counsel her that lobectomy is both diagnostic and therapeutic: if the final pathology is benign, no further surgery is needed; if it is malignant, completion thyroidectomy may be required. I would not offer total thyroidectomy upfront unless she has contralateral disease or a strong family history. Shared decision-making should include her anxiety and voice concerns.
2. If she undergoes right lobectomy and final pathology shows a 3 cm follicular thyroid carcinoma with capsular invasion only, what is the role of completion thyroidectomy and radioiodine?
Read the worked answer
This is a minimally invasive follicular thyroid carcinoma with capsular invasion only, 3 cm, in a 38-year-old. According to risk stratification, it is low risk. Completion thyroidectomy is not mandatory for low-risk tumours <4 cm with capsular invasion only, because lobectomy alone may be adequate and avoids the risk of contralateral recurrent laryngeal nerve injury. However, completion thyroidectomy may be considered to facilitate radioiodine ablation if there are adverse features or if the patient prefers more aggressive management. Radioiodine is generally not indicated for low-risk disease with complete resection and no vascular invasion, because the benefit is unproven and there are risks of salivary gland damage and second malignancies. I would discuss surveillance with neck ultrasound and thyroglobulin, and the option of completion surgery. Given her singing career, I would favour avoiding completion thyroidectomy unless there is a clear oncological benefit. I would also ensure she is on levothyroxine if she becomes hypothyroid. This is a shared decision with endocrinology and nuclear medicine.